Phaseline

Companies › Renata

Renata: clinical trials, targets and expected readouts

1 active drug program in 10 registered trials: 5 Phase 4, 3 Phase 2, 2 Phase 1; Hematology, Oncology, Other.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Eltrombopag
Thrombopoietin receptor agonist
MPLPhase 1Primary Immune Thrombocytopenia; Healthy; Hematological Neoplasms; ITP - Immune Thrombocytopenia …–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT04600960EltrombopagPhase 2Chemotherapy-induced ThrombocytopeniaHematologyMar 2025
NCT06531018EltrombopagPhase 1Primary Immune ThrombocytopeniaHematologyAug 2025
NCT06834451EltrombopagPhase 4HealthyOtherOct 2025
NCT03844360EltrombopagPhase 4Hematological NeoplasmsOncologyDec 2026
NCT07788456EltrombopagPhase 4ITP - Immune ThrombocytopeniaHematologyMay 2027
NCT03206086EltrombopagPhase 2Fanconi AnemiaHematologyAug 2028
NCT04518475EltrombopagPhase 4Primary Immune Thrombocytopenia (ITP)HematologyFeb 2029
NCT04518475EltrombopagPhase 4Primary Immune Thrombocytopenia (ITP)HematologyFeb 2029
NCT01623167EltrombopagPhase 1Severe Aplastic AnemiaHematologyNov 2029
NCT04304820EltrombopagPhase 2Severe Aplastic AnemiaHematologyDec 2033

Targets

MPL (1)

Companies with the same targets

Novartis Jiangsu HengRui Medicine Amgen

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.